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ABSTRACT 
The pathological phenomenon of somatopause, noticeable in hypogonadal ageing subjects, is based on the growth 
hormone (GH) production and secretion decrease along with the fall in GH binding protein and insulin-like growth 
factor 1 (IGF-1) levels, causing different musculoskeletal, metabolic and mental issues. From the perspective of 
safety and efficacy, GH treatment is considered to be highly controversial, while some other therapeutic ap-
proaches (application of IGF-1, GH secretagogues, gonadal steroids, cholinesterase-inhibitors or various combi-
nations) exhibit more or less pronounced weaknesses in this respect. Soy isoflavones, phytochemicals that have 
already demonstrated the health benefits in treated elderly, at least experimentally reveal their potential for the 
somatopausal symptoms remediation. Namely, genistein enhanced GHRH-stimulated cAMP accumulation and 
GH release in rat anterior pituitary cells; refreshed and stimulated the somatotropic system (hypothalamic nuclei 
and pituitary GH cells) function in a rat model of the mild andropause, and stimulated the GH output in ovariec-
tomized ewes as well as the amplitude of GH pulses in the rams. Daidzein, on the other hand, increased body mass, 
trabecular bone mass and decreased bone turnover in the animal model of severe andropause, while both isofla-
vones demonstrated blood cholesterol-lowering effect in the same model. These data, which necessarily need to 
be preclinically and clinically filtered, hint some cautious optimism and call for further innovative designing of 
balanced soy isoflavone-based therapeutics. 
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INTRODUCTION 
Ageing represents a complex 
phenomenon characterized by the temporal, 
social and psychophysiological dimension. 
While the temporal one is general and 
intuitively clear, reflecting the time flow, the 
two other dimensions are interconnected and 
have some gender-related specificities. 
Female ageing is outlined by initial continuity 
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of the process, leading to the fertility-related 
milestone – the menopause, a “point of 
discontinuity“ or the specific life transition 
associated with an increase in various health 
risk factors including cardiovascular issues, 
osteoporosis, diabetes or cancer (Perry et al., 
2015; Koebele and Bimonte-Nelson, 2016). 
Some psychological disorders considering 
low moods, depression, anxiety states, 
insomnia, changes in cognition or reduction 
of sexual interest also accompany the post-
menopausal period of life (Pearce and 
Hawton, 1996; Santoro et al., 2015). An 
abrupt and permanent cessation of the ovarian 
function is responsible for the menopausal 
transition (Calabrese et al., 2014; Ajdžanović 
et al., 2017a). Ovarian cell loss begins even 
prenatally in numerous female mammals, 
deriving exponential depletion of primary 
follicles and oocytes, associated with loss of 
fecundity by midlife (Finch, 2014). In the 
post-menopause, follicle-stimulating hormo-
ne levels are significantly higher, estradiol 
levels are fallen, while inhibin B and anti-
Mullerian hormone are undetectable (Burger 
et al., 2007). Reconsideration of the role and 
purpose in life, personality, interpersonal 
relationships or body image influence the 
experience of menopause in the social terms 
(Deeks, 2004). On the other hand, male 
ageing is progressive and gradual in its 
essence, while low free testosterone is the key 
characteristic of the hormonal status of ageing 
males (Gray et al., 1991; Chahal and Drake, 
2007; Ajdžanović et al., 2015a, 2016). So far 
accumulated data indicate ageing-induced 
decrease in the Leydig cell steroidogenic 
capacity with an increase in cyclooxygenase-
2 activity and its’ tonic inhibition of 
steroidogenic acute regulatory gene express-
ion; lowered Sertoli cell function and number, 
decline in seminiferous tubule volume and 
sperm content, as well as raised germ cells 
apoptosis rate (Wang et al., 2002; Wang and 
Stocco, 2005). Diminished endogenous 
testosterone production, enabling circulating 
free testosterone lower than 220 pmol/L, 
grounds a specific multi-symptomatic 
syndrome known as andropause or late-onset 
hypogonadism (LOH) (Vance, 2003; 
Morales, 2004; Singh, 2013). To be precise, 
primary hypogonadism (testicular failure) as 
well as the secondary hypogonadism 
(hypothalamic-pituitary-gonadal axis failure) 
entirely represent the phenomenon of 
andropause (Golan et al., 2015). Similarly to 
the menopausal women, various psycho-
social issues like depression, lack of 
motivation, lower psychological vitality, 
anxiety, irritability, insomnia, difficulty in 
concentrating, memory impairment, decreas-
ed work performances, low dominance and 
decreased libido are observable in the ageing 
men (Amore, 2005). 
The neuroendocrine regulation of the 
ageing process is attracting intensive attention 
of the investigators during the current epoch 
of a dramatic increase in the elderly people 
share (Jones and Boelaert, 2015). Ageing-
induced extinction/dysfunction of the 
regulatory hippocampal, hypothalamic and 
limbic neurons and synapses and the 
compensatory gliosis (Mani et al., 1986; 
Ferrari et al., 2001) are followed with a 
decrease of hormonal secretion within 
majority of the neuroendocrine axes, reduced 
sensitivity of tissues to hormonal actions and 
the loss of normal circadian rhythms (Jones 
and Boelaert, 2015). Additionally to 
previously mentioned, ageing-related 
structural and functional disorders of the 
reproductive system (menopause and 
andropause) as well as the hypothalamic-
pituitary-adrenal (HPA) axis perturbations 
during ageing (adrenopause) linked with 
metabolic syndrome and cardiovascular 
issues, hypogonadal ageing subjects 
frequently suffer from the loss of growth axis 
function (somatopause), associated with 
reductions in skeletal muscle and bone 
mass/strength (Ferrari and Mantero, 2005; 
Lombardi et al., 2005; Golan et al., 2015; 
Jones and Boelaert, 2015). The impression is 
that the somatopausal perspective of 
musculoskeletal issues in elderly received 
insufficient attention within the research 
circles. 
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Hormone replacement therapy (HRT) of 
the ageing subjects appears to be an 
acceptable medical approach, considering 
that the irreversible age-related changes at the 
tissue/organic level almost entirely exclude 
the causal therapy modalities (Beg et al., 
2008; Shifren and Shiff, 2010; Ajdžanović et 
al., 2015a, 2016). Significant benefits 
pertinent to the prevention of menopausal 
osteoporosis as well as the management of a 
certain psychological disorders, frequent in 
this period of female life, are observed upon 
menopausal estrogen therapy (Al-Safi and 
Santoro, 2014; Cauley, 2015). In line with 
this, the affirmative aspects of testosterone 
application to ageing males have included the 
prevention or reversion of bone deterioration, 
glucocorticoid hypersecretion, sexual dys-
function and depression (Myers and 
Meacham, 2003; Amore et al., 2009; 
Ajdžanović et al., 2017b). Treatment with 
growth hormone (GH) during ageing was 
considered as a possible “fountain of youth”, 
hence as some good solution in improving the 
functional status of elderly (Clayton et al., 
2007; Sattler, 2013). However, keeping in 
mind the possible harmful effects of estrogen 
replacement therapy (thromboembolism, 
breast or endometrial cancer development) or 
following the testosterone supplementation 
(prostate cancer development, cardiovascular 
issues, hepatotoxicity), careful selection of 
dosage and duration of their use is strongly 
recommended (Grady et al., 2000; Fournier et 
al., 2003; Myers and Meacham, 2003; 
Jockenhövel, 2003; Albert and Morley, 
2016). Also, although GH therapy has been 
shown to exert positive effects in GH-
deficient patients, it is known that 
GH/insulin-like growth factor 1 (IGF-1) 
deficiency may result in prolonged life 
expectancy, at least in animals (Giordano et 
al., 2008). Different authors generally 
consider the GH treatment as highly 
controversial, from the perspective of safety, 
efficacy and its exact role in elderly 
individuals (Shim and Cohen, 1999; Liu et al., 
2007; Giordano et al., 2008). 
When it comes to the focus of 
biomedically-oriented part of the scientific 
community, the past two decades have been 
in the sign of massive investigation at the field 
of plant-derived, preferably safe and 
effective, alternatives to HRT. A complex 
array of polyphenolic, bioactive non-nutrients 
isolated from vegetables, legumes, cereals, 
fruits or tea, also known as phytochemicals, 
have demonstrated significant health benefits 
upon consumption either as an integral part of 
the food or as a food supplement/alternative 
remedy (Adlercreutz and Mazur, 1997; 
Setchell, 1998; Tham et al., 1998; Chanet et 
al., 2012). 
Soy isoflavones (commonly genistein, 
daidzein and equol – Figure 1) represent 
diphenolic, estrogen-like compounds that 
may exist without or with glucose residues 
attached (aglycones or 7-O-β-D glucosides). 
They perform weak estrogenic and anti-
estrogenic activity both in vitro and in vivo 
(Price and Fenwick, 1985). Also, soy 
isoflavones manifest tyrosine kinase 
inhibiting effects (Akiyama et al., 1987) and 
strong antioxidative activity (Benassayag et 
al., 2002). Representative studies have shown 
that some positive outcome could be noticed 
in soy isoflavone treatment of breast and 
prostate cancer, osteoporosis, coronary heart 
disease, as well as ageing-related psych-
ological symptoms (Casini et al., 2006; 
Messina, 2010; Messina et al., 2010; Andres 
et al., 2011). The research experience that 
qualifies us for an credible opinion related to 
soy isoflavone effects during ageing is based 
on a multi-year exploitation of different rat 
models of andropause and menopause, in the 
context of these compounds application 
(Ajdžanović et al., 2009a,b, 2011, 2012, 
2014a,b; Milošević et al., 2009; Filipović et 
al., 2007, 2010; Šošić-Jurjević et al., 2007, 
2010, 2012, 2014; Pantelić et al., 2013; 
Trifunović, 2012; Trifunović et al., 2012, 
2014a,b, 2016; Medigović et al., 2015). The 
general scarcity of data concerning the soy 
isoflavone effects in somatopause, together 
with the fact that our ageing rat models, 
besides numerous neuroendocrine axes 
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disturbancies, manifest the somatopausal 
symptoms also, highlight the reported soy 
isoflavone role in their, at least partly, 
alleviation (Trifunović, 2012; Ajdžanović et 
al., 2014a; Trifunović et al., 2014b, 2016). 
This analytical text is inter alia devoted to 
detailed, experimentally grounded elabora-
tion of soy isoflavone-mediated effects 
through the somatotropic i.e. GH/IGF-1 
system in ageing models. 
 
 
Figure 1: The chemical structures of soy 
isoflavones 
 
 
PHENOMENOLOGY OF THE 
SOMATOPAUSE 
Somatotropic system 
Somatotropic system plays the essential 
role in the hormonal regulation of postnatal 
growth and development in mammals. The 
system covers regulation of the GH (also 
known as somatotropin) secretion from 
pituitary somatotropes (GH cells), GH 
distribution and its actions in peripheral 
tissues, interaction with the specific GH 
receptors (GHr), as well as the endocrine, 
paracrine and autocrine responses, mostly 
mediated by IGF-1 (Figure 2). Hypothalamic 
regulatory centers, anterior pituitary, 
peripheral target tissues and different 
receptors and signal molecules belong to the 
somatotropic system (Giustina and Veldhuis, 
1998; Le Roith et al., 2001). The numerous 
inter-constituent interactions within the 
system are modulated by different 
neurotransmitters and neuropeptides, sex 
steroids, corticosteroids, thyroxine and some 
metabolic signals. GH affects a variety of 
target tissues and organs, like skeletal 
muscles, bones, liver, gastrointestinal tract, 
brain, heart, kidneys, mammary glands, 
ovaries, testes, spleen, thymus, bone marrow 
and skin (Veldhuis et al., 2005). Somatotropic 
system plays the crucial regulatory role in 
protein, carbohydrate and lipid metabolism 
(Daughaday, 1992), while GH stimulates the 
liver IGF-1 biosynthesis, thus ensuring the 
presence of its most important mediator in the 
physiological action (Haymond and Mauras, 
1996; Le Roith et al., 2001). However, in 
some type of cells, like chondrocytes and 
mature adipocytes, GH action is IGF-1 
independent (Hwa et al., 1999). The 
somatotropic system activity could be 
influenced by the environmental, metabolic 
and hormonal factors, including hunger, 
obesity, injuries, sexual activity as well as 
glucocorticoid and thyroid status. These 
factors affect both hypothalamic regulation of 
GH production/secretion and the following 
response of the target tissues (Giustina and 
Veldhuis, 1998). It should be emphasized that 
GH is in mammals secreted as a series of 
pulses. In normal young individuals, a major 
secretory episode occurs shortly after sleep 
onset and coincides with the first period of 
slow-wave sleep (Van Cauter et al., 1998). 
The crucial GH secretion regulators are 
two hypothalamic hormones – growth 
hormone-releasing hormone (GHRH) and 
somatostatin (SS). Presence of different 
GHRH and SS concentrations in the pituitary 
portal bloodstream leads towards different 
GH concentrations in the systemic 
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circulation, enabling GH release when portal 
SS level is low and the related GHRH level is 
high (Tannenbaum and Ling, 1984; Plotsky 
and Vale, 1985). The mechanism of GH 
release, regulated by these two neuropeptides, 
involves adenylate cyclase/cAMP pathway 
and the intracellular Ca2+ changes 
(Bilezikjian and Vale, 1983; Frohman and 
Jansson, 1986; Lussier et al., 1991a). Increase 
of the cAMP levels triggers the Na+ channels 
opening, membrane depolarization and Ca2+ 
influx via the L-type of Ca2+ channels 
(Lussier et al., 1991b; Naumov et al., 1994). 
The increase of intracellular Ca2+ is the basis 
of GH release, realised over the exocytosis 
process. Production of cAMP and GH release 
also depends on some additional signal 
mechanisms, including protein kinase C, 
tyrosine kinase, diacyglycerol and 
phospholipase (Cronin et al., 1986; Ogiwara 
et al., 1997). In line with this, there are some 
data decribing GHRH influence on GH gene 
transcription through cAMP-dependent 
process (Clayton et al., 1986). 
Figure 2: Internal regulation of the somatotropic 
system functioning 
 
 
The third hormone involved in the 
regulation of GH secretion is 28 amino acids-
containing acylated peptide ghrelin (van der 
Lely et al., 2004). It is dominantly produced 
in stomach, while some considerably lower 
concentrations of the hormone are detected in 
guts, pancreas, kidneys, lungs, immune 
system, placenta, testes, pituitary and 
hypothalamus (Korbonits et al., 2001; Lu et 
al., 2001). Ghrelin stimulates GH release 
synergistically with GHRH, after binding to 
GH-secretagogue receptors (Kojima et al., 
1999). Somatomedin- (especially IGF-1) as 
well as the own GH-negative feedback 
additionally control GH release (Giustina and 
Veldhuis, 1998). 
 
GENERAL CONSIDERATIONS OF 
SOMATOPAUSAL SYMPTOMS AND 
THE MORPHOPHYSIOLOGICAL 
BASIS OF SOMATOPAUSE 
In the advanced period of life, production 
and secretion of GH decrease in parallel with 
the fall in GH binding protein and IGF-1 
levels, all of which is often encircled using the 
complex term - somatopause (Sattler, 2013; 
Junnila et al., 2013). Actually, production of 
GH was far ago reported to decline by 14 % 
per life decade (Iranmanesh et al., 1991). 
While pubertal boys produce 1.0-1.5 mg/day 
of GH, in aged men this hormone level is 
around 50 μg/day (Veldhuis et al., 1995). 
During middle-age and after that period 35 % 
of men were found to be GH deficient 
(Rudman et al., 1990). Basically, the 
contribution of sleep-dependent GH release to 
the daily output in women is lower and more 
variable than in men (Van Cauter et al., 1998). 
It was observed that the mean GH release and 
pulse amplitude are significantly lower in 
aged, unrestrained female rhesus monkeys 
than in young female individuals (Woller et 
al., 2002). In women, the fall in GH release is 
amplitude- rather than frequency-modulated 
and it was linked to estrogen status (Ho and 
Weissberger, 1990). Somatopause is 
regularly followed with reductions in skeletal 
muscle and bone mass/strength (sarcopenia, 
osteopenia or osteoporosis), weakness, 
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frailty, loss of physical functions and vitality, 
central adiposity, cardiovascular risks and 
deterioration of mental function (Lombardi et 
al., 2005; Sattler, 2013). 
Mechanisms responsible for the age-
dependent instability of GH release include 
both peripheral influences (gonadal steroid 
levels, adiposity) and, more important, 
changes in hypothalamic neuropeptides and 
neurotransmitters entwined with decreased 
GHRH secretion as well as SS hypersecretion 
(Müller et al., 1995; Ghigo et al., 1996; Arvat 
et al., 1999; Veldhuis et al., 2002). Giordano 
et al. (2005) point out that the hypofunction of 
somatotropic system in ageing represents the 
impressive example of decreased activity as a 
consequence of age-related changes in the 
neural control of GH cells. It shouldn't be 
overlooked that the age-related variations in a 
natural GH secretagogue ghrelin effects could 
play an important role in the decreased GH 
secretion in elderly subjects (van der Lely et 
al., 2004; Arvat et al., 2000). 
 
Somatopause through the lens of animal 
studies 
In order to precisely and consistently 
position the phenomenon of somatopause in 
the context of animal studies, we need some 
broader perspective of the GH/IGF-1 
deficiency models analyze. Namely, while the 
creation of various knockout animal models 
enables general investigation of the GH/IGF-
1 deficiency consequences, somatopause per 
se is usually being identified in parallel with 
the other morphophysiological signs of 
deterioration in the animal models of ageing. 
Low GH and IGF-1 levels characterize 
specifically genetically modified inverte-
brates Caenorhabditis elegans and Droso-
phila melanogaster used for the ageing 
studies, as well as laboratory rodents known 
as lit/lit mice, Ames dwarf, Snell dwarf, 
Lewis dwarf or Laron dwarf (Junnila et al., 
2013; Sattler, 2013). Knockout of prop-1 
producing Ames dwarfs and Pit-1 producing 
Snell dwarfs results in GH/IGF-1 deficiency 
(Brown-Borg et al., 1996; Flurkey et al., 
2001). Pit-1 encodes the protein necessary for 
the differentiation of pituitary GH, thyroid-
stimulating hormone (TSH) and prolactin 
cells, so Snell mice lack all three hormones 
(Li et al., 1990). Similarly, GH-deficient 
Ames dwarf mice possess mutation in the 
prop-1 gene responsible for the expression of 
‘homeobox protein prophet of Pit-1’ (Junilla 
et al., 2013). On the other hand, Laron dwarf 
mice manifest GH receptor mutation and are 
GH-resistant, with decreased IGF-1 levels 
(Coschigano et al., 2003). It should be 
highlighted that dwarf animal models, with 
decreased tone of the somatotropic system, 
have extended longevity (Junnila et al., 2013). 
They were proposed to be protected from 
cancer and diabetes mellitus, two widely 
spread ageing-related morbidities, due to the 
affection of critical cellular regulatory 
systems involved in response to stress, 
metabolism or energy balance (Junnila et al., 
2013; Sattler, 2013). Interestingly, the 
Kopchick laboratory experience with the lines 
of mice suffering from targeted GHr deletion, 
limited to the specific tissues (adipose, liver, 
skeletal or cardiac muscle), indicates the lack 
of global GHr deletion effects on longevity 
(Bartke et al., 2016). 
Herein, we have no intention to 
polemicize with the argumented attitude 
pertinent to the longevity of GH/IGF-1 
deficient animal models, but tend to 
emphasize the somatopause-related indicators 
in the animal ageing models, attributable to 
the quality of life. Our accumulated 
experience in the field of experimental ageing 
results from the exploitation of Wistar rat 
models of andropause and menopause. 
Considering the importance of the ‘stereology 
approach’, as essential in the discovery of 
important concepts in the variety of cell 
biology investigations (von Bartheld and 
Wouters, 2015), the stereological counting in 
our laboratory is performed using microscopy 
on the histological tissue sections, as a 
method of semi-automated, computer-based 
microscopy systems (newCast, Visiopharm, 
Denmark). Before elaboration of detected 
degenerative changes of the somatotropic 
system, present in these models, we will 
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respectively describe its normal features in 
adult rats used as the controls, as well as the 
features of somatotropic system in the ageing 
controls. 
In the first instance, we will focus on adult 
male rats that have preserved central 
regulation of endocrine processes and provide 
the control values for comparison with the 
adequate ones after orchidectomy 
(orchidectomized adult male rats represent 
animal model of the mild andropause). The 
mean body mass of sham-operated, control 
adult male rats in our experiment amounted 
362.4 ± 36.3 g (Trifunović, 2012). The 
average absolute pituitary weight was 12.9 ± 
1.1 mg, while the average pituitary volume 
was 5.5 ± 0.6 mm3, in the same animals 
(Trifunović, 2012; Trifunović et al., 2014b). 
GHRH immunoreactive neurons, located in 
the ventrolateral portion of the hypothalamic 
arcuate (Arc) nucleus, demonstrated a clear 
immunofluorescent staining characteristics in 
sham-operated adult male rats (Figure 3a) 
(Trifunović, 2012; Trifunović et al., 2016). SS 
immunoreactivity, expressed in the neurons 
located within a discrete zone of the 
hypothalamic periventricular (Pe) nucleus, 
alongside the third brain ventricle, is also 
found to be distinctive in the same group of 
rats (Figure 3d) (Trifunović, 2012; Trifunović 
et al., 2016). Besides these two specified 
hypothalamic nuclei, GHRH and SS 
noticeable immunoreactivities were likewise 
identified in the median eminence (ME), a 
structure at the base of the hypothalamus, of 
our control adult male rats (Figure 4a,d) 
(Trifunović, 2012; Trifunović et al., 2016). 
The average volume of Arc nucleus amounted 
0.175 ± 0.017 mm3 while the same parameter 
of Pe nucleus was 0.259 ± 0.014 mm3, in 
sham-operated adults (Trifunović, 2012; 
Trifunović et al., 2016). In line with this, 
volume density of GHRH neurons in Arc 
nucleus and volume density of SS neurons in 
Pe nucleus were around 14% and 7.9 ± 0.8%, 
respectively (Trifunović et al., 2016). GH 
cells are the predominant cell phenotype in 
the anterior pituitary of adult male rats 
(Takahashi, 1992; Milošević et al., 1998; 
Milošević, 2001). In our male controls, 
immunohistochemically labelled GH cells 
varied from round or ovoid to pyramidal and 
ellipsoid in shape, and possessed a large, 
spherical, eccentrally located nucleus (Figure 
5a inset) (Milošević et al., 1998; Trifunović, 
2012; Trifunović et al., 2014b). The cell 
distribution was even and considered either 
the presence of clusters or a single cell 
between capillaries, in the pituitary pars 
distalis (Figure 5a) (Milošević et al., 1998; 
Trifunović, 2012; Trifunović et al., 2014b). 
The mean value of GH cell volume density 
amounted 23.8 ± 0.87 %, while the numerical 
density of GH cells was 16.4 ± 1.4 x 104 mm-3, 
in sham-operated male rats (Trifunović, 
2012). The total number of GH cells was 7.0 
± 0.3 x 105 and the GH cell volume amounted 
1498.0 ± 109.2 μm3, in the same adult group 
(Trifunović, 2012; Trifunović et al., 2014b). 
Finally, the circulating concentration of GH 
was 3.6 ± 0.4 ng/ml, in the sham-operated 
controls (Trifunović, 2012; Trifunović et al., 
2014b).  
In orchidectomized adult male rats 
(animal model of the mild andropause), the 
mean body mass amounted 330.4 ± 32.3 g and 
was significantly (p<0.05) decreased in 
comparison with the sham-operated adult 
controls (Trifunović, 2012). After 
orchidectomy, the average absolute pituitary 
weight was 14.9 ± 1.1 mg, which represented 
the increase when compared to the control 
value, while the average pituitary volume was 
6.1 ± 0.6 mm3 and remained almost 
unchanged (Trifunović, 2012; Trifunović et 
al., 2016). GHRH immunoreactivity in the 
Arc nucleus as well as SS immunostaining in 
the Pe nucleus, of orchidectomized adult 
males, were less noticeable than in sham-
operated controls (Figure 3b, e) (Trifunović, 
2012; Trifunović et al., 2016). In line with 
this, the ME-related staining intensities of 
GHRH and SS neurons were lower (p<0.05) 
after orchidectomy of adult rats (Figure 4b, e)
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Figure 3: Somatotropic system hypothalamic regulatory neurons in: a, d) So – sham operated, b, e) 
Orx – orchidectomized and c, f) Orx+G – genistein treated orchidectomized adult male rats (Trifunović, 
2012; Trifunović et al., 2016). GHRH - growth hormone-releasing hormone neurons, SS – somatostatin 
neurons, Arc - hypothalamic arcuate nucleus, Pe - hypothalamic periventricular nucleus. White and 
black arrows are directed towards the representative GHRH and SS neurons. Orchidectomized adult 
male rats represent animal model of the mild andropause. 
 
 
(Trifunović, 2012; Trifunović et al., 2016). 
The volume of the Arc nucleus was 33 % 
(p<0.05) larger in orchidectomized than that 
in sham-operated adults, while orchidectomy 
did not provoke changes of the Pe nucleus 
volume in relation to the same control group 
(Trifunović et al., 2016). Upon orchidectomy, 
the volume densities of GHRH neurons in the 
Arc nucleus and of SS neurons in the Pe 
nucleus were decreased (p<0.05) by 22 % and 
42 % respectively, in comparison with sham-
operated control animals (Trifunović, 2012; 
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Trifunović et al., 2016). The visual 
impression of GH cell histological 
appearance in orchidectomized adult rats 
implied their decreased number and staining 
intensity, with unchanged shape and size, all 
related to sham-operated controls (Figure 5b) 
(Trifunović, 2012; Trifunović et al., 2016). 
After orchidectomy, the mean value of GH 
cell volume density decreased by 22 % 
(p<0.05) while their numerical density was 
almost unchanged, compared to 
corresponding parameters in sham-operated 
rats (Trifunović, 2012; Trifunović et al., 
2016). The total number of GH cells, their 
volume as well as the circulating 
concentration of GH remained insignificantly 
changed in orchidectomized adult male rats 
when compared to the adequate values in 
sham-operated control males (Trifunović, 
2012; Trifunović et al., 2016). It can be 
concluded that the most prominent 
degenerative changes of the somatotropic 
system in an animal model of the mild 
andropause (namely, after elimination of 
endogenous sex steroids from the hormonal 
milieu) were observable at the level of 
hypothalamic regulatory GHRH and SS 
neurons in Arc and Pe nucleus respectively, 
as well as in the ME of hypothalamus, while 
the GH cells suffered of decreased hormone 
production and the reduction of volume 
density.
 
 
Figure 4: Somatotropic system hypothalamic regulatory neurons in: a, d) So – sham operated, b, e) 
Orx – orchidectomized and c, f) Orx+G – genistein treated orchidectomized adult male rats (Trifunović, 
2012; Trifunović et al., 2016). GHRH - growth hormone-releasing hormone neurons, SS – somatostatin 
neurons, ME – median eminence. White arrows indicate the representative GHRH and SS 
immunoreactivity.
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Figure 5: Immunolabeled GH cells in: a) So – 
sham operated, b) Orx – orchidectomized and c) 
Orx+G – genistein treated orchidectomized adult 
male rats (Trifunović, 2012; Trifunović et al., 
2014b). 
 
 
For the other rat model of the andropause 
we exploited, orchidectomized middle-aged 
(16-month-old) male rats – the model of 
severe andropause, sham-operated middle-
aged males provided the values used in the 
comparison. The mean body mass of middle-
aged control males amounted 650.0 ± 29.0 g 
(Ajdžanović et al., 2014a). Their average 
absolute pituitary weight was 17.0 ± 1.7 mg 
and the average relative pituitary weight was 
2.2 ± 0.1 mg/100 g body mass. Like in sham-
operated adult male rat pituitaries, 
imunopositive GH cells in sham-operated 
middle-aged males were uniformly 
distributed (Figure 6a) in the pars distalis, 
while being completely absent in the pituitary 
pars intermedia (Ajdžanović et al., 2014a). 
We have observed either an individual GH 
cell or a group of them, especially near the 
sinusoidal capillaries (Figure 6a) (Ajdžanović 
et al., 2014a). Also, the GH cells appeared 
massive, ovoid to pyramidal in shape, with a 
spherical, centrally located nucleus (Figure 
6a) (Ajdžanović et al., 2014a). The immuno-
specific/immunofluorescent signal, reflecting 
the GH cells hormonal content, was 
pronounced and widely distributed through-
out the cytoplasm (Figure 6a, 7a) (Ajdžanović 
et al., 2014a). The morphometric analysis 
revealed that a mean GH cell volume 
amounted almost 600 μm3, while their volume 
density was around 36 %, in sham-operated 
middle-aged rats (Ajdžanović et al., 2014a). It 
should be noticed that some ageing-induced, 
somatotropic system-related differences 
between our adult and middle-aged male 
controls are visible, especially when it comes 
to the GH cell volume and volume density. 
Our animal model of severe andropause 
(orchidectomized middle-aged male rats; the 
central regulation of endocrine processes is 
disturbed) was characterized by almost 10 % 
decrease in the mean body mass, when 
compared to the same parameter in sham-
operated middle-aged rats (Ajdžanović et al., 
2014a). Orchidectomy-caused testosterone 
elimination from the hormonal millieu of this 
model did not affect on TSH and thyroxine 
circulating levels, but significantly increased 
cholesterol (total, LDL and HDL) blood 
concentrations (Šošić-Jurjević et al., 2007, 
2012). While the average absolute pituitary 
weight was not significantly changed in the 
orchidectomized model males, the average 
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relative pituitary weight was significantly 
(p<0.05) increased by 13.6 %, in comparison 
with the sham-operated controls. There were 
no observed differences between 
orchidectomized and sham-operated middle-
aged rats when it comes to the GH cell 
distribution, grouping, shape, nuclei 
positioning and the immunospecific/immuno-
fluorescent signal (Figure 6b, 7b) (Ajdžano-
vić et al., 2014a). Also, the GH cell volume, 
nuclei volume and volume density were not 
significantly changed after orchidectomy of 
middle-aged male rats (Ajdžanović et al., 
2014a). Obviously, the elimination of 
circulating sex steroids achieved by 
orhidectomy did not additionally promote 
some degenerative changes of the somato-
tropic system (GH cell morphometric 
parameters) in middle-aged male rats. In 
parallel, a series of bone homeostasis-related 
parameter values measured after 
orchidectomy indicated the presence of 
trabecular bone deterioration in this animal 
model (Filipović et al., 2007, 2010, 2013; 
Ajdžanović et al., 2017b). 
Finally, a few text rows will be given to 
the somatotropic system-related changes in 
middle-aged female rats (14-month-old; 
animal model of the menopause), used in our 
experimental praxis (Milošević et al., 2000, 
2005). The mean body mass, as well as the 
average absolute and relative pituitary weight 
values were considerably higher in middle-
aged females than in adult female controls 
(Milošević et al., 2000, 2005). On the other 
hand, the morphometric parameters of 
immunopositive GH cells i.e. the cell volume, 
nuclei volume and volume density, together 
with circulating GH, have synchronously 
fallen with ageing of female rats (Milošević et 
al., 2000, 2005). Accordingly, the female 
ageing rat model is characterized by distinct 
impairment of the somatotropic system 
operative component (GH cells) habitus and 
function, no matter the regular process of a 
mass/weights rise. 
 
 
Figure 6: Immunolabeled GH cells in: a) So – 
sham operated, b) Orx – orchidectomized, c) 
Orx+G – genistein treated and d) Orx+D - 
daidzein treated orchidectomized middle-aged 
male rats; magnification 63x, bar=16 μm 
(Ajdžanović et al., 2014a). Orchidectomized 
middle-aged rats represent animal model of the 
severe andropause. 
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Figure 7: Immunofluorescent appearance of GH 
cells in: a) So – sham operated, b) Orx – orchi-
dectomized, c) Orx+G – genistein treated and d) 
Orx+D - daidzein treated orchidectomized middle-
aged male rats; bar=20 μm (Ajdžanović et al., 
2014a). 
Clinical recognition of the somatopause 
and weaknesses of existing therapeutic 
approaches 
Similarly to the situation in an animal 
model of ageing, where the somatopausal 
symptoms are identified in parallel with the 
other morphophysiological signs of 
deterioration, clinical recognition of the 
somatopause merges in a wider horizon of 
degenerative changes occuring with advanced 
age. Since we have above already mentioned 
the clinical signs of somatopause, it can be 
said that ageing-caused (patho)physiological 
changes within the human body are similar to 
those observed in GH deficiency, while the 
GH treatment was considered to be beneficial 
when it comes to the maximum oxygen 
consumption and overall life quality 
(Lombardi et al., 2005; Clayton et al., 2007). 
However, despite the optimistic thesis, 
randomized and controlled studies revealed 
that the effects of GH treatment in healthy 
elderly subjects actually are less promising 
(Lamberts, 2000; Lombardi et al., 2005). It 
was reported that an increase in muscle mass 
upon GH treatment is followed by improved 
muscle strength only if the exercise is 
intensified (Lamberts, 2000). Some up-to-
date meta-analysis of randomized clinical 
trials suggests that GH treatment, applied to 
the subjects with the risk of osteoporosis, 
results in non-significant increases of bone 
mineral density (Atkinson et al., 2017). 
Furthermore, one year of IGF-1 application to 
postmenopausal women, in a dose (15 μg/kg, 
twice a day) sufficient to elevate circulating 
IGF-1 to young normal values, was not 
effective in altering the body composition or 
improvement of bone density, strength, mood 
and memory of these women (Friedlander et 
al., 2001). Also, GH treatment in the elderly 
appeared problematic for some additional 
reasons. It was shown that GH administration 
in healthy ageing subjects frequently caused 
dose-dependent fluid retention, insulin 
resistance/increased glucose, gynecomastia 
and carpal tunnel syndrome (Rudman et al., 
1990; Yuen et al., 2004; Liu et al., 2007; 
Giordano et al., 2008). On the other hand, an 
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increased cancer rate linked to the GH 
treatment in elderly has not been reported, 
probably due to short-lasting clinical trials or 
a specific timing of the therapy (end of the 
life), when there is not enough time for a 
cancer development (Giordano et al., 2008). 
Given that the hypofunction of 
somatotropic system in ageing mostly reflects 
disturbance in the neural control of GH 
secretion, treatment with GHRH or GH 
secretagogues has also been proposed in 
elderly people (Aimaretti et al., 2004; 
Giordano et al., 2008). Some short-lasting 
GHRH treatments have been shown to restore 
spontaneous GH secretion and IGF-1 levels in 
the ageing subjects (Corpas et al., 1992), but 
there was no increase in physical performance 
scores upon its administration (Borst, 2004). 
Additionally, the crucial problem of GHRH 
use in the clinical praxis is that it needs to be 
parenterally administered (Giordano et al., 
2008). GH secretagogues, as a synthetic 
peptide or non-peptide substance, may 
stimulate GH secretion by acting at the 
pituitary or at the level of hypothalamic 
GHRH neurons (Ghigo et al., 1999). While 
peptidergic GH secretagogues were 
ineffective on the GH/IGF-1 levels in elderly 
people (Rahim et al., 1998), some non-
peptidergic analogues applied to the same 
population stimulated the GH secretion, that 
have restored the IGF-1 production at the 
young subject values (Aloi et al., 1994). The 
expressed concern related to these 
secretagogues is whether they can 
significantly affect the body composition, 
metabolism or cognitive functions associated 
with ageing (Giordano et al., 2008). 
Keeping in mind that the somatopause 
coincides with low free testosterone in ageing 
(andropausal) men, it seems logical that the 
testosterone supplementation may be 
considered as a therapeutic strategy in the 
elimination of the symptoms. It was observed 
that transdermal testosterone application (5 
mg/day, 5-6 weeks) to elderly (61-76 years 
old) men did not alter neither GH pulse 
frequency and amplitude nor the maximal GH 
peak (Orrego et al., 2004). Judging from the 
fact that testosterone supplementation to 
healthy elderly men was not effective in the 
normalization of pituitary GH output, the 
authors concluded that age-related 
testosterone deficiency is unlikely to be the 
proximate cause of the somatopause (Orrego 
et al., 2004). When it comes to the 
simultaneous treatment of ageing male with 
GH and testosterone, results appear to be 
controversial. While the certain studies 
suggest the lack of positive interaction 
between these two hormones in the impact on 
muscle performance (Giannoulis et al., 2006), 
there is some evidence of significantly 
increased aerobic capacity/muscle mass and 
decreased total abdominal fat during the 
treatment with the combination (Blackman et 
al., 2002; Giannoulis et al., 2012; Sattler, 
2013). On the other hand, the estrogen 
replacement was suggested to affect GH 
responsiveness by causing relative GH 
resistance (Gleeson and Shalet, 2009). 
Münzer et al. (2006) observed some slightly 
increased IGF-1 levels in healthy aged 
women, upon the hormone replacement 
therapy (100 μg/day estradiol patch plus 
2.5 mg of medroxyprogesterone acetate, for 
the first 10 days of each month/26 weeks). 
The similar pattern of estradiol treatment, 
alone or combined with GH, did not 
significantly affect a muscle strenght in 
healthy aged women (Blackman et al., 2002). 
Besides the hormone supplementation 
strategies in a service of the recovery of 
somatopausal symptoms, a certain number of 
pharmaceuticals are developed for that 
purpose. Thus, cerebral selective cholin-
esterase-inhibitors (rivastigmine and done-
pezil) were shown to be beneficial for the 
enhancement of GH release and the elevation 
of IGF-1 levels in elderly human subjects, but 
their long-term efficacy and safety remained 
questionable (Obermayr et al., 2003, 2005). 
Additionally, alfacalcidol (1-hydroxy-
cholecalciferol), which is an analogue of 
vitamin D, has performed the multifactorial 
effects on the somatopause familiar 
symptoms (Schacht et al., 2005). The best 
known are its anti-bone loss effect, as well as 
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the action on muscle power, which reduces 
falls and the related bone fractures (Schacht et 
al., 2005). 
In the section of this analytical text that 
follows, we will accentuate the effects of soy 
isoflavones on the somatotropic system in the 
experimental in vivo models. As above 
mentioned, polyphenols of natural origin, 
especially soy isoflavones, possess the 
evidence-based potential in the remediation 
of wide spectrum of ageing-related symptoms 
and diseases. Their effects at the level of 
morphophysiological and pathological basis 
of the somatopause should receive the 
deserved attention. Soy isoflavone abundant 
presence in the specific foods (tofu, miso, soy 
milk, soy sauce, etc.), the proportionally low 
cost of purified compounds, a simple 
formulation in the food supplements or 
alternative remedies and the related facilitated 
administration, all together additionally 
recommend their usage in this respect. 
However, their potentially endocrine-
disrupting effects shouldn't be disregarded in 
designing the therapeutic strategy (Bennetau-
Pelissero, 2016). 
 
THE SOY ISOFLAVONE EFFECTS 
WITHIN THE SOMATOTROPIC 
SYSTEM OF EXPERIMENTAL 
MODELS 
Considering the above mentioned 
weaknesses of existing therapeutic 
approaches pertinent to the somatopausal 
symptoms, as well as the known side effects 
of “classical” HRT, we believe that the 
research efforts should be made to identify 
some agents that may have a better 
risk/benefit profile. Currently, there is the 
credible opinion that polyphenols of natural 
origin could be a good and relatively safe 
replacement for the hormone therapy. A 
detailed mechanistic overview of soy 
isoflavone actions, that may be useful while 
reading this section, can be found in our 
previous review articles (Ajdžanović et al., 
2014b, 2015b). 
In an attempt to light up the potential 
usefulness/weakness of soy-isoflavone 
supplementation when it comes to the 
somatotropic system in different ex-
perimental models (dominantly the ageing 
ones), the relevant research data is 
summarized in this section. Far ago was 
shown that genistein had enhanced GHRH-
stimulated cAMP accumulation and GH 
release in rat anterior pituitary cells (Ogiwara 
et al., 1997). The Trifunović et al. (2012, 
2014b, 2016) respectable studies de-
monstrated the effects of soy isoflavone 
genistein on the analytical and quanititative 
histology-related parameters of somatotropic 
system and GH output in a rat model of the 
mild andropause (orchidectomized adult rats). 
As already stated, some modern stereological 
tools were used in the obtaining of results. 
The applied dose of genistein (30 mg/kg b.m.) 
was chosen to mimic human exposure to 
elevated concentrations of isoflavones 
(Doerge and Sheehan, 2002). Precisely, 
following the genistein treatment we found an 
increase of the Arc nucleus volume by 24 % 
while Pe nucleus volume didn’t change, 
compared to the orchidectomized control 
(Trifunović et al., 2016). Morphological 
remodeling of the neurons and glial cells via 
ERs could be responsible for the larger Arc 
nucleus volume, considering improved 
neuronal cell proliferation observed in some 
brain regions upon genistein application in 
vitro (Pan et al., 2012). Visible GHRH 
immunoreactivity in the Arc nucleus as well 
as SS immunoreactivity in the Pe nucleus 
were detected upon genistein treatment of 
orchidectomized adult rats (Figure 3c, f) 
(Trifunović et al., 2016). Also, genistein 
treatment led to higher volume density of the 
Arc GHRH neurons by 26 % and improved 
GHRH intensity of staining in the ME, all 
compared to the control (Figure 4c), probably 
operating through the ER-dependent 
mechanisms, considering that 70 % of those 
neurons express ERs (Kamegai et al., 2001; 
Trifunović et al., 2016). The volume density 
of SS neurons was 1.5 fold higher, followed 
with higher SS imunofluorescence intensity 
in the ME (Figure 4f), all after genistein 
treatment, probable as the result of this 
EXCLI Journal 2018;17:279-301 – ISSN 1611-2156 
Received: November 06, 2017, accepted: March 10, 2018, published: March 21, 2018 
 
 
293 
isoflavone indirect action through an 
intraneuronal system (Herbison and 
Theodosis, 1993; Trifunović et al., 2016). At 
the pituitary level, genistein treatment 
increased pituitary weight by 28 % and the 
volume by 21 %, in comparison with the 
orhidectomy alone (Trifunović et al., 2014b). 
The volume density and total number of GH 
cells were 18 % and 36 % higher in genistein 
treated group than in the orchidectomized 
controls, respectively (Figure 5c) (Trifunović 
et al., 2014b). Plus, there was a tendency for 
the GH cell volume to be greater following 
treatment with this isoflavone (Figure 5c 
inset) (Trifunović et al., 2014b). The 
stimulating action of genistein on the 
stereological data within hypothalamus and 
pituitary has led to increased concentration of 
GH. Precisely, the GH blood concentration 
was higher by 1.3 fold in comparison with the 
orchidectomized control group (Trifunović et 
al., 2014b). It is evident that genistein 
refreshed and stimulated the somatotropic 
system function in a rat model of the mild 
andropause. In line with this, the elevation of 
circulating GH as well as the increase of the 
expression levels of the GHr in the liver tissue 
has been found in Sprague-Dawley rats 
treated (10 days) with cheonggukjang, a 
fermented soybean product rich in genistein 
and daidzein (Hwang et al., 2014). 
In the animal model of severe andropause 
(orchidectomized middle-aged rats), applied 
genistein or daidzein (30 mg/kg b.m.) 
returned the mean body mass at a level 
observed in sham-operated group, i.e. 
increased its value in comparison with the 
control group where only the orchidectomy 
was performed (Ajdžanović et al., 2014a). 
After daidzein treatment, the absolute and 
relative pituitary weights were increased by 
8.4 % and 15 % respectively, while in 
genistein treated group the relative pituitary 
weight increased by 24 %, all compared to the 
orchidectomized control group (Ajdžanović 
et al., 2014a). The main characteristic of GH 
cells in genistein or daidzein treated rats is a 
weaker intensity of immunospecific staining 
compared to the orchidectomized group, 
while the pituitary capillaries, towards which 
GH cells gravitate, are dilated (Figure 6c, d). 
Relative intensity of fluorescence within the 
pituitary GH cells was decreased by 44.8 % 
and 50 %, following genistein and daidzein 
treatment, respectively (Figure 7c, d). Also, 
the volume of GH cells was smaller by 13.8 % 
and 11.9 %, while their relative volume 
density was decreased by 65.4 % and 64 %, 
all following genistein and daidzein 
treatments respectively (Figure 6c, d) 
(Ajdžanović et al., 2014a). Also, our findings 
indicate that daidzein treatment stimulated 
thyroid C cells, increased trabecular bone 
mass and decreased bone turnover in the same 
animal model (Filipović et al., 2010). Low 
dosed genistein or daidzein (10 mg/kg b.m.) 
were shown to increase TSH, decrease 
thyroid hormone circulating levels as well as 
to increase the peripheral tissue availability of 
thyroid hormones, all when applied in the 
animal model of severe andropause (Šošić-
Jurjević et al., 2010, 2014). The cholesterol 
(total, LDL and HDL) blood concentrations 
significantly decreased, but the total 
triglyceride circulating concentrations 
increased, upon low (10 mg/kg b.m.) and high 
(30 mg/kg b.m.) genistein or daidzein 
application to orchidectomized middle-aged 
rats (Šošić-Jurjević et al., 2007). Appearance 
of the somatotropic system and the related 
biochemical/physiological parameters, re-
flecting the soy isoflavone application in the 
animal model of severe andropause, are not 
all in the perfect coherence when it comes to 
the potential benefit of the substances' 
supplementation. Namely, the observed 
triglyceride concentrations increase call for 
some precautions, while the GH blood 
concentration should be measured for the 
purpose of confirmation of intensified GH 
cell-hormonal content secretion. 
It should be emphasized that intracerebro-
ventricular (ICV) infusion of genistein 
(40 μg/400 μl/4 h), applied to ovariectomized 
ewes six weeks after the surgery, increased 
the mean plasma GH concentrations in 
comparison with the control values (Misztal 
et al., 2007). Results from the same study 
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showed the decreased values of GH-positive 
cells percentage as well as the GH 
immunostaining density, suggesting 
diminished hormone storage and its 
intensified secretion (Misztal et al., 2007). 
Obviously, in an animal model represented by 
estradiol-deprived females (like in meno-
pause), genistein stimulated the GH output, 
which from the musculoskeletal point of view 
may be considered as a positive outcome. 
Also, the stimulation of the amplitude of GH 
pulses was observed by the same research 
group in the rams ICV treated with genistein 
(total 40 μg) (Misztal et al., 2008). 
Finally, some studies show the effects of 
genistein on the somatotropic system that 
should be also taken into account. Thus, the 
study on the Nile tilapia fish (Oreochromis 
niloticus) was conducted to examine the 
effects of dietary genistein on the endocrine 
disruption on GH/IGF-1 system (Chen et al., 
2016). There weren’t changes in the plasma 
GH and IGF-1 levels in fish fed with diets 
containing 30 μg/g and 300 μg/g genistein, 
while the mRNA expression of genes along 
the GH/IGF-1 system remained unaffected 
(Chen et al., 2016). In the fish fed with 
3000 μg/g genistein diet, the plasma GH and 
IGF-1 levels decreased, and the mRNA 
expression of GH and GHr2 was depressed 
(Chen et al., 2016). This study provides 
convincing evidence for the growth 
impediment after high-dosed genistein 
application, by disturbing the GH/IGF-1 axis, 
in Nile tilapia Oreochromis niloticus (Chen et 
al., 2016). 
To the best of our knowledge, the changes 
of somatotropic system upon soy isoflavone 
application haven’t been clinically monitored, 
yet. In addition to beneficial bone- and 
metabolism-related clinical findings, 
pertinent to their usage (Zhuo et al., 2004; 
Messina, 2010; Jackson et al., 2011; Cavallini 
et al., 2016), this specific aspect deserves a 
greater attention. 
 
CONCLUSION 
From the previous detailed elaboration of 
somatopause phenomenology and the 
weaknesses/uncertainties related to existing 
therapeutic approaches, it is clear that there is 
a need for discovering some more effective, 
and at the same time safe alternatives. It 
seems that soy isoflavones, potentially cheap 
substances whose easy application shows a 
number of benefits when it comes to the wide 
spectrum of ageing symptoms, may play a 
certain role in this context. At least, the 
presented data from experimental ageing 
studies, which necessarily need to be 
preclinically and clinically filtered regarding 
the somatopausal symptoms, hint some 
cautious optimism and call for further 
designing of balanced soy isoflavone-based 
therapeutics. 
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